I-124

RADIATION2 trials

Sponsors

University of Wuerzburg, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions

Differentiated Thyroid CarcinomaThyroid Cancer

Phase 2

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

RecruitingNCT03841617

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Thyroid Cancer

Start: 2019-07-29End: 2035-11-01Target: 30Updated: 2026-09-09

Unknown Phase

I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer

Active, not recruitingNCT01704586

University of WuerzburgDifferentiated Thyroid Carcinoma

Start: 2015-05-01End: 2031-05-01Target: 340Updated: 2026-05-12

Related Papers

CLERAD-PROBE: Dosimetric analysis of I-124 PET–guided remnant radioiodine ablation in differentiated thyroid carcinoma.

Journal of Clinical Oncology2026-05-27